{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:37:12Z","timestamp":1792705032216,"version":"4.5.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11912-022-01202-6","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:04:28Z","timestamp":1644451468000},"page":"399-414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Cancer Immunotherapies: What the Perioperative Physician Needs to Know"],"prefix":"10.1007","volume":"24","author":[{"given":"Robert S.","family":"Ackerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Muncey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin N.","family":"Aldawoodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Kotha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarie E. Garcia","family":"Getting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"issue":"5","key":"1202_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41571-019-0319-9","volume":"17","author":"P Matzner","year":"2020","unstructured":"Matzner P, Sandbank E, Neeman E, Zmora O, Gottumukkala V, Ben-Eliyahu S. Harnessing cancer immunotherapy during the unexploited immediate perioperative period. Nat Rev Clin Oncol. 2020;17(5):313\u201326. https:\/\/doi.org\/10.1038\/s41571-019-0319-9.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1202_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40425-018-0398-7","volume":"6","author":"O Bakos","year":"2018","unstructured":"Bakos O, Lawson C, Rouleau S, Tai LH. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 2018;6(1):86. https:\/\/doi.org\/10.1186\/s40425-018-0398-7.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1202_CR3","first-page":"375","volume":"10","author":"B Bondhopadhyay","year":"2020","unstructured":"Bondhopadhyay B, Sisodiya S, Chikara A, Khan A, Tanwar P, Afroze D, et al. Cancer immunotherapy: a promising dawn in cancer research. Am J Blood Res. 2020;10(6):375\u201385.","journal-title":"Am J Blood Res"},{"issue":"3","key":"1202_CR4","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1213\/ane.0000000000005607","volume":"133","author":"RS Ackerman","year":"2021","unstructured":"Ackerman RS, Luddy KA, Icard BE, Pi\u00f1eiro Fern\u00e1ndez J, Gatenby RA, Muncey AR. The effects of anesthetics and perioperative medications on immune function: a narrative review. Anesth Analg. 2021;133(3):676\u201389. https:\/\/doi.org\/10.1213\/ane.0000000000005607.","journal-title":"Anesth Analg"},{"issue":"1","key":"1202_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13046-019-1266-0","volume":"38","author":"S Kruger","year":"2019","unstructured":"Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, et al. Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res. 2019;38(1):268. https:\/\/doi.org\/10.1186\/s13046-019-1266-0.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"1202_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10120-020-01090-4","volume":"23","author":"K Kono","year":"2020","unstructured":"Kono K, Nakajima S, Mimura K. Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer. 2020;23(4):565\u201378. https:\/\/doi.org\/10.1007\/s10120-020-01090-4.","journal-title":"Gastric Cancer"},{"issue":"5","key":"1202_CR7","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.jtcvs.2020.05.119","volume":"160","author":"BM Stiles","year":"2020","unstructured":"Stiles BM, Sepesi B, Broderick SR, Bott MJ. Perioperative considerations for neoadjuvant immunotherapy in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2020;160(5):1376\u201382. https:\/\/doi.org\/10.1016\/j.jtcvs.2020.05.119.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"1202_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s40140-018-0303-4","volume":"8","author":"T Andrabi","year":"2018","unstructured":"Andrabi T, French KE, Qazilbash MH. New cancer therapies: implications for the perioperative period. Curr Anesthesiol Rep. 2018;8(4):362\u20137. https:\/\/doi.org\/10.1007\/s40140-018-0303-4. Review of cancer treatments and toxicities for the anesthesiologist.","journal-title":"Curr Anesthesiol Rep"},{"key":"1202_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349. https:\/\/doi.org\/10.1146\/annurev-pathol-042020-042741.","journal-title":"Annu Rev Pathol"},{"key":"1202_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fonc.2017.00121","volume":"7","author":"AW Elias","year":"2017","unstructured":"Elias AW, Kasi PM, Stauffer JA, Thiel DD, Colibaseanu DT, Mody K, et al. The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors: a retrospective study. Front Oncol. 2017;7:121. https:\/\/doi.org\/10.3389\/fonc.2017.00121.","journal-title":"Front Oncol"},{"key":"1202_CR11","doi-asserted-by":"publisher","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","volume":"92","author":"S Hussaini","year":"2021","unstructured":"Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis. Cancer Treat Rev. 2021;92:102134. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102134.","journal-title":"Cancer Treat Rev"},{"key":"1202_CR12","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3389\/fimmu.2020.02023","volume":"11","author":"Y Xu","year":"2020","unstructured":"Xu Y, Fu Y, Zhu B, Wang J, Zhang B. Predictive biomarkers of immune checkpoint inhibitors-related toxicities. Front Immunol. 2020;11:2023. https:\/\/doi.org\/10.3389\/fimmu.2020.02023.","journal-title":"Front Immunol"},{"issue":"4","key":"1202_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","volume":"19","author":"AM Haugh","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 2020;19(4):479\u201388. https:\/\/doi.org\/10.1080\/14740338.2020.1738382.","journal-title":"Expert Opin Drug Saf"},{"key":"1202_CR14","doi-asserted-by":"publisher","first-page":"574271","DOI":"10.3389\/fimmu.2020.574271","volume":"11","author":"R Franzin","year":"2020","unstructured":"Franzin R, Netti GS, Spadaccino F, Porta C, Gesualdo L, Stallone G, et al. The use of immune checkpoint inhibitors in oncology and the occurrence of aki: where do we stand? Front Immunol. 2020;11:574271. https:\/\/doi.org\/10.3389\/fimmu.2020.574271.","journal-title":"Front Immunol"},{"key":"1202_CR15","doi-asserted-by":"publisher","unstructured":"S\u0142awi\u0144ski G, Wrona A, D\u0105browska-Kugacka A, Raczak G, Lewicka E. Immune checkpoint inhibitors and cardiac toxicity in patients treated for non-small lung cancer: a review. Int J Mol Sci. 2020;21(19). https:\/\/doi.org\/10.3390\/ijms21197195.","DOI":"10.3390\/ijms21197195"},{"issue":"18","key":"1202_CR16","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/jco.2014.60.0379","volume":"33","author":"JS Weber","year":"2015","unstructured":"Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33(18):2092\u20139. https:\/\/doi.org\/10.1200\/jco.2014.60.0379.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1202_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.jopan.2020.08.007","volume":"35","author":"AC Robinson","year":"2020","unstructured":"Robinson AC, Wolfe RC. Immune checkpoint inhibitors and perioperative considerations. J Perianesth Nurs. 2020;35(6):687\u201391. https:\/\/doi.org\/10.1016\/j.jopan.2020.08.007.","journal-title":"J Perianesth Nurs"},{"issue":"1","key":"1202_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/bor.0000000000000672","volume":"32","author":"P Boland","year":"2020","unstructured":"Boland P, Heath J, Sandigursky S. Immune checkpoint inhibitors and vasculitis. Curr Opin Rheumatol. 2020;32(1):53\u20136. https:\/\/doi.org\/10.1097\/bor.0000000000000672.","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"1202_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86\u2013104. https:\/\/doi.org\/10.3322\/caac.21596.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1202_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.bja.2019.11.034","volume":"124","author":"AL Lewis","year":"2020","unstructured":"Lewis AL, Chaft J, Girotra M, Fischer GW. Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. Br J Anaesth. 2020;124(3):251\u201360. https:\/\/doi.org\/10.1016\/j.bja.2019.11.034. Review of immune checkpoint inhibitor therapy, toxicity, and anesthetic implications.","journal-title":"Br J Anaesth"},{"key":"1202_CR21","doi-asserted-by":"publisher","unstructured":"Market M, Baxter KE, Angka L, Kennedy MA, Auer RC. The potential for cancer immunotherapy in targeting surgery-induced natural killer cell dysfunction. Cancers (Basel). 2018;11(1). https:\/\/doi.org\/10.3390\/cancers11010002.","DOI":"10.3390\/cancers11010002"},{"issue":"1","key":"1202_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1089\/jir.2018.0019","volume":"39","author":"KC Conlon","year":"2019","unstructured":"Conlon KC, Miljkovic MD, Waldmann TA. Cytokines in the treatment of cancer. J Interferon Cytokine Res. 2019;39(1):6\u201321. https:\/\/doi.org\/10.1089\/jir.2018.0019.","journal-title":"J Interferon Cytokine Res"},{"issue":"20","key":"1202_CR23","first-page":"5765","volume":"52","author":"PH Nichols","year":"1992","unstructured":"Nichols PH, Ramsden CW, Ward U, Sedman PC, Primrose JN. Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. Cancer Res. 1992;52(20):5765\u20139.","journal-title":"Cancer Res"},{"issue":"2","key":"1202_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/jir.2017.0101","volume":"38","author":"JM Wrangle","year":"2018","unstructured":"Wrangle JM, Patterson A, Johnson CB, Neitzke DJ, Mehrotra S, Denlinger CE, et al. IL-2 and beyond in cancer immunotherapy. J Interferon Cytokine Res. 2018;38(2):45\u201368. https:\/\/doi.org\/10.1089\/jir.2017.0101.","journal-title":"J Interferon Cytokine Res"},{"issue":"9","key":"1202_CR25","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ni.3518","volume":"17","author":"C Guillerey","year":"2016","unstructured":"Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17(9):1025\u201336. https:\/\/doi.org\/10.1038\/ni.3518.","journal-title":"Nat Immunol"},{"issue":"25","key":"1202_CR26","doi-asserted-by":"publisher","first-page":"e3951","DOI":"10.1097\/md.0000000000003951","volume":"95","author":"M Shi","year":"2016","unstructured":"Shi M, Chen X, Ye K, Yao Y, Li Y. Application potential of toll-like receptors in cancer immunotherapy: Systematic review. Medicine (Baltimore). 2016;95(25):e3951. https:\/\/doi.org\/10.1097\/md.0000000000003951.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"1202_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/01.tp.0000188124.42726.d8","volume":"81","author":"J Obhrai","year":"2006","unstructured":"Obhrai J, Goldstein DR. The role of toll-like receptors in solid organ transplantation. Transplantation. 2006;81(4):497\u2013502. https:\/\/doi.org\/10.1097\/01.tp.0000188124.42726.d8.","journal-title":"Transplantation"},{"key":"1202_CR28","doi-asserted-by":"publisher","first-page":"2045860","DOI":"10.1155\/2020\/2045860","volume":"2020","author":"JY Noh","year":"2020","unstructured":"Noh JY, Yoon SR, Kim TD, Choi I, Jung H. Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy. J Immunol Res. 2020;2020:2045860. https:\/\/doi.org\/10.1155\/2020\/2045860.","journal-title":"J Immunol Res"},{"issue":"5","key":"1202_CR29","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11523-018-0589-7","volume":"13","author":"MJ Braunstein","year":"2018","unstructured":"Braunstein MJ, Kucharczyk J, Adams S. Targeting toll-like receptors for cancer therapy. Target Oncol. 2018;13(5):583\u201398. https:\/\/doi.org\/10.1007\/s11523-018-0589-7.","journal-title":"Target Oncol"},{"issue":"6","key":"1202_CR30","doi-asserted-by":"publisher","first-page":"e12818","DOI":"10.1111\/sji.12818","volume":"90","author":"S Ohadian Moghadam","year":"2019","unstructured":"Ohadian Moghadam S, Nowroozi MR. Toll-like receptors: the role in bladder cancer development, progression and immunotherapy. Scand J Immunol. 2019;90(6):e12818. https:\/\/doi.org\/10.1111\/sji.12818.","journal-title":"Scand J Immunol"},{"issue":"3","key":"1202_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40268-020-00314-3","volume":"20","author":"S Monestime","year":"2020","unstructured":"Monestime S, Lazaridis D. Pexidartinib (TURALIO\u2122): The first FDA-indicated systemic treatment for tenosynovial giant cell tumor. Drugs R D. 2020;20(3):189\u201395. https:\/\/doi.org\/10.1007\/s40268-020-00314-3.","journal-title":"Drugs R D"},{"issue":"16","key":"1202_CR32","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","volume":"79","author":"YN Lamb","year":"2019","unstructured":"Lamb YN. Pexidartinib: first approval. Drugs. 2019;79(16):1805\u201312. https:\/\/doi.org\/10.1007\/s40265-019-01210-0.","journal-title":"Drugs"},{"issue":"10197","key":"1202_CR33","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/s0140-6736(19)30764-0","volume":"394","author":"WD Tap","year":"2019","unstructured":"Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394(10197):478\u201387. https:\/\/doi.org\/10.1016\/s0140-6736(19)30764-0.","journal-title":"Lancet"},{"key":"1202_CR34","unstructured":"Administration USFD. Drugs@FDA: FDA-Approved Drugs page. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm. Accessed August 20 2021."},{"key":"1202_CR35","unstructured":"Epocrates. Epocrates Drug Lookup page. https:\/\/online.epocrates.com\/drugs. Accessed August 20 2021."},{"key":"1202_CR36","volume-title":"Cellular and molecular immunology","author":"AK LA Abbas","year":"2017","unstructured":"LA Abbas AK, Pillai S. Cellular and molecular immunology. Philadelphia: Elsevier; 2017."},{"issue":"4","key":"1202_CR37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443\u20136. https:\/\/doi.org\/10.1038\/74704.","journal-title":"Nat Med"},{"key":"1202_CR38","unstructured":"Genentech, Inc. RITUXAN (rituximab) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103705s5464lbl.pdf. Revised June 2021. Accessed August 20, 2021."},{"key":"1202_CR39","unstructured":"Genentech, Inc. HERCEPTIN (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103792s5250lbl.pdf. Revised October 2010. Accessed August 20, 2021."},{"key":"1202_CR40","unstructured":"Genentech, Inc. AVASTIN (bevacizumab) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125085s337lbl.pdf. Revised Decemeber 2020. Accessed August 20, 2021."},{"issue":"3","key":"1202_CR41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/s1368-7646(03)00040-2","volume":"6","author":"JS Chen","year":"2003","unstructured":"Chen JS, Lan K, Hung MC. Strategies to target HER2\/neu overexpression for cancer therapy. Drug Resist Updat. 2003;6(3):129\u201336. https:\/\/doi.org\/10.1016\/s1368-7646(03)00040-2.","journal-title":"Drug Resist Updat"},{"issue":"8","key":"1202_CR42","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc2403","volume":"8","author":"LM Ellis","year":"2008","unstructured":"Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8(8):579\u201391. https:\/\/doi.org\/10.1038\/nrc2403.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1202_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","volume":"27","author":"RM Lu","year":"2020","unstructured":"Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. https:\/\/doi.org\/10.1186\/s12929-019-0592-z.","journal-title":"J Biomed Sci"},{"key":"1202_CR44","doi-asserted-by":"publisher","unstructured":"McKertish CM, Kayser V. Advances and Limitations of Antibody Drug Conjugates for Cancer. Biomedicines. 2021;9(8). https:\/\/doi.org\/10.3390\/biomedicines9080872.","DOI":"10.3390\/biomedicines9080872"},{"key":"1202_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-019-0175-x","volume":"7","author":"B Yu","year":"2019","unstructured":"Yu B, Liu D. Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia. Biomark Res. 2019;7:24. https:\/\/doi.org\/10.1186\/s40364-019-0175-x.","journal-title":"Biomark Res"},{"key":"1202_CR46","unstructured":"Spectrum Pharmaceuticals. ZEVALIN (ibritumomab tiuxetan) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125019s227lbl.pdf. Revised December 2018. Accessed August 20, 2021."},{"issue":"13","key":"1202_CR47","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","volume":"76","author":"SL Moores","year":"2016","unstructured":"Moores SL, Chiu ML, Bushey BS, Chevalier K, Luistro L, Dorn K, et al. A novel bispecific antibody targeting EGFR and cMet is effective against egfr inhibitor-resistant lung tumors. Cancer Res. 2016;76(13):3942\u201353. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2833.","journal-title":"Cancer Res"},{"issue":"8","key":"1202_CR48","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585\u2013608. https:\/\/doi.org\/10.1038\/s41573-019-0028-1.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1202_CR49","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.20908","volume":"115","author":"P Hoffmann","year":"2005","unstructured":"Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005;115(1):98\u2013104. https:\/\/doi.org\/10.1002\/ijc.20908.","journal-title":"Int J Cancer"},{"issue":"1","key":"1202_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","volume":"21","author":"F Kroschinsky","year":"2017","unstructured":"Kroschinsky F, Stolzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21(1):89. https:\/\/doi.org\/10.1186\/s13054-017-1678-1.","journal-title":"Crit Care"},{"issue":"1","key":"1202_CR51","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/CCM.0000000000004087","volume":"48","author":"C Gutierrez","year":"2020","unstructured":"Gutierrez C, McEvoy C, Munshi L, Stephens RS, Detsky ME, Nates JL, et al. Critical care management of toxicities associated with targeted agents and immunotherapies for cancer. Crit Care Med. 2020;48(1):10\u201321. https:\/\/doi.org\/10.1097\/CCM.0000000000004087. Review of immunotherapy toxicities that require critical care.","journal-title":"Crit Care Med"},{"issue":"3","key":"1202_CR52","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jaip.2016.12.001","volume":"5","author":"M Picard","year":"2017","unstructured":"Picard M, Galvao VR. Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. J Allergy Clin Immunol Pract. 2017;5(3):600\u20139. https:\/\/doi.org\/10.1016\/j.jaip.2016.12.001.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1202_CR53","unstructured":"United Therapeutics Corporation. UNITUXIN (dinutuximab) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125516s025lbl.pdf. Revised September 2020. Accessed August 20, 2021."},{"key":"1202_CR54","unstructured":"Y-mAbs Therapeutics. DANYELZA (naxitamab-gqgk) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761171lbl.pdf. Revised November 2020. Accessed August 20, 2021."},{"key":"1202_CR55","doi-asserted-by":"publisher","first-page":"e27987","DOI":"10.4161\/onci.27987","volume":"3","author":"NG Kounis","year":"2014","unstructured":"Kounis NG, Soufras GD, Tsigkas G, Hahalis G. Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome. Oncoimmunology. 2014;3:e27987. https:\/\/doi.org\/10.4161\/onci.27987.","journal-title":"Oncoimmunology"},{"issue":"10","key":"1202_CR56","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1515\/cclm-2016-0010","volume":"54","author":"NG Kounis","year":"2016","unstructured":"Kounis NG. Kounis syndrome: an update on epidemiology, pathogenesis, diagnosis and therapeutic management. Clin Chem Lab Med. 2016;54(10):1545\u201359. https:\/\/doi.org\/10.1515\/cclm-2016-0010.","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"1202_CR57","first-page":"218","volume":"37","author":"JT Poterucha","year":"2010","unstructured":"Poterucha JT, Westberg M, Nerheim P, Lovell JP. Rituximab-induced polymorphic ventricular tachycardia. Tex Heart Inst J. 2010;37(2):218\u201320.","journal-title":"Tex Heart Inst J"},{"key":"1202_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08879-w","author":"JL Waldron","year":"2021","unstructured":"Waldron JL, Schworer SA, Kwan M. Hypersensitivity and immune-related adverse events in biologic therapy. Clin Rev Allergy Immunol. 2021. https:\/\/doi.org\/10.1007\/s12016-021-08879-w.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"1202_CR59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","volume":"188","author":"N Dempsey","year":"2021","unstructured":"Dempsey N, Rosenthal A, Dabas N, Kropotova Y, Lippman M, Bishopric NH. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat. 2021;188(1):21\u201336. https:\/\/doi.org\/10.1007\/s10549-021-06280-x.","journal-title":"Breast Cancer Res Treat"},{"issue":"22","key":"1202_CR60","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol. 2019;73(22):2859\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.495.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1202_CR61","doi-asserted-by":"publisher","first-page":"pkaa076","DOI":"10.1093\/jncics\/pkaa076","volume":"4","author":"MT Van Leeuwen","year":"2020","unstructured":"Van Leeuwen MT, Luu S, Gurney H, Brown MR, Pearson SA, Webber K, et al. Cardiovascular toxicity of targeted therapies for cancer: an overview of systematic reviews. JNCI Cancer Spectr. 2020;4(6):pkaa076. https:\/\/doi.org\/10.1093\/jncics\/pkaa076. Review of cardiotoxicity with targeted agents.","journal-title":"JNCI Cancer Spectr"},{"issue":"7","key":"1202_CR62","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","volume":"16","author":"N Thatcher","year":"2015","unstructured":"Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16(7):763\u201374. https:\/\/doi.org\/10.1016\/S1470-2045(15)00021-2.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1202_CR63","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00280-013-2146-5","volume":"71","author":"JF Deeken","year":"2013","unstructured":"Deeken JF, Shimkus B, Liem A, Hill D, Gurtler J, Berghorn E, et al. Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors. Cancer Chemother Pharmacol. 2013;71(6):1473\u201383. https:\/\/doi.org\/10.1007\/s00280-013-2146-5.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1202_CR64","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00280-016-3074-y","volume":"78","author":"DC Smith","year":"2016","unstructured":"Smith DC, Powderly J, Lee JJ, Shepard DR, Wallin J, Chaudhary A, et al. Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;78(2):271\u201380. https:\/\/doi.org\/10.1007\/s00280-016-3074-y.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1202_CR65","doi-asserted-by":"publisher","unstructured":"Jeong GH, Lee KH, Lee IR, Oh JH, Kim DW, Shin JW et al. Incidence of Capillary leak syndrome as an adverse effect of drugs in cancer patients: a systematic review and meta-analysis. J Clin Med. 2019;8(2). https:\/\/doi.org\/10.3390\/jcm8020143.","DOI":"10.3390\/jcm8020143"},{"issue":"1","key":"1202_CR66","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","volume":"183","author":"MD Hackshaw","year":"2020","unstructured":"Hackshaw MD, Danysh HE, Singh J, Ritchey ME, Ladner A, Taitt C, et al. Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020;183(1):23\u201339. https:\/\/doi.org\/10.1007\/s10549-020-05754-8.","journal-title":"Breast Cancer Res Treat"},{"issue":"43","key":"1202_CR67","doi-asserted-by":"publisher","first-page":"e22795","DOI":"10.1097\/MD.0000000000022795","volume":"99","author":"SC Chien","year":"2020","unstructured":"Chien SC, Chien SC, Hu TY. Rapid-onset acute respiratory distress syndrome after mastectomy in a breast cancer patient: A case report and review of literature. Medicine (Baltimore). 2020;99(43):e22795. https:\/\/doi.org\/10.1097\/MD.0000000000022795.","journal-title":"Medicine (Baltimore)"},{"key":"1202_CR68","doi-asserted-by":"publisher","unstructured":"McFaline-Figueroa JR, Lee, E.Q. Neurological complications of targeted therapies and immunotherapies for cancer. Curr Treat Options Neurol. 2021;23(9). https:\/\/doi.org\/10.1007\/s11940-021-00663-7. Review of immunotherapy associated neurotoxicy.","DOI":"10.1007\/s11940-021-00663-7"},{"issue":"9","key":"1202_CR69","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1136\/rapm-2021-102557","volume":"46","author":"A Herijgers","year":"2021","unstructured":"Herijgers A, Van Dyck L, Leroy I, Dobbels L, Van de Putte PBC. Spinal anesthesia in a patient on monoclonal antibody treatment: a poisoned chalice? A case report. Reg Anesth Pain Med. 2021;46(9):828\u201330. https:\/\/doi.org\/10.1136\/rapm-2021-102557.","journal-title":"Reg Anesth Pain Med"},{"key":"1202_CR70","unstructured":"Sanofi Genzyme. LEMTRADA (alemtuzumab) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103948s5183lbl.pdf. Revised August 2021. Accessed September 1, 2021. ."},{"key":"1202_CR71","unstructured":"Innate Pharma S.A. LUMOXITI (moxetumomab pasudotox-tdfk) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761104s003lbl.pdf. Revised August 2020. Accessed September 1, 2021."},{"issue":"11","key":"1202_CR72","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1634\/theoncologist.2017-0055","volume":"22","author":"BD Cheson","year":"2017","unstructured":"Cheson BD, Heitner Enschede S, Cerri E, Desai M, Potluri J, Lamanna N, et al. Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents. Oncologist. 2017;22(11):1283\u201391. https:\/\/doi.org\/10.1634\/theoncologist.2017-0055.","journal-title":"Oncologist"},{"issue":"4","key":"1202_CR73","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1053\/j.ackd.2017.05.006","volume":"24","author":"J Lefebvre","year":"2017","unstructured":"Lefebvre J, Glezerman IG. Kidney toxicities associated with novel cancer therapies. Adv Chronic Kidney Dis. 2017;24(4):233\u201340. https:\/\/doi.org\/10.1053\/j.ackd.2017.05.006.","journal-title":"Adv Chronic Kidney Dis"},{"key":"1202_CR74","doi-asserted-by":"publisher","first-page":"204209862091505","DOI":"10.1177\/2042098620915058","volume":"11","author":"AM Cobert","year":"2020","unstructured":"Cobert AM, Helms C, Larck C, Moore DC. Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis. Ther Adv Drug Saf. 2020;11:2042098620915058. https:\/\/doi.org\/10.1177\/2042098620915058.","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"1202_CR75","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/10428194.2020.1827247","volume":"62","author":"A Ladha","year":"2021","unstructured":"Ladha A, Mannis G, Muffly L. Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin. Leuk Lymphoma. 2021;62(2):257\u201363. https:\/\/doi.org\/10.1080\/10428194.2020.1827247.","journal-title":"Leuk Lymphoma"},{"key":"1202_CR76","doi-asserted-by":"publisher","first-page":"685706","DOI":"10.3389\/fonc.2021.685706","volume":"11","author":"X Cao","year":"2021","unstructured":"Cao X, Wang Y, Li P, Huang W, Lu X, Lu H. HBV reactivation during the treatment of non-hodgkin lymphoma and management strategies. Front Oncol. 2021;11:685706. https:\/\/doi.org\/10.3389\/fonc.2021.685706.","journal-title":"Front Oncol"},{"key":"1202_CR77","unstructured":"Gilead Sciences, Inc. TRODELVY (sacituzumab govitecan-hziy) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761115s009lbl.pdf. Revised April 2021. Accessed August 20, 2021."},{"key":"1202_CR78","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.3389\/fimmu.2018.02616","volume":"9","author":"G Lancman","year":"2018","unstructured":"Lancman G, Arinsburg S, Jhang J, Cho HJ, Jagannath S, Madduri D, et al. Blood transfusion management for patients treated with anti-cd38 monoclonal antibodies. Front Immunol. 2018;9:2616. https:\/\/doi.org\/10.3389\/fimmu.2018.02616.","journal-title":"Front Immunol"},{"issue":"2","key":"1202_CR79","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1213\/ANE.0000000000004201","volume":"129","author":"G Echeverry","year":"2019","unstructured":"Echeverry G, Fischer GW, Mead E. Next generation of cancer treatments: chimeric antigen receptor t-cell therapy and its related toxicities: a review for perioperative physicians. Anesth Analg. 2019;129(2):434\u201341. https:\/\/doi.org\/10.1213\/ANE.0000000000004201. Review of CAR-T toxicity with perioperative implications.","journal-title":"Anesth Analg"},{"key":"1202_CR80","doi-asserted-by":"publisher","unstructured":"Rath JA, Arber C. Engineering strategies to enhance tcr-based adoptive t cell therapy. Cells. 2020;9(6). https:\/\/doi.org\/10.3390\/cells9061485.","DOI":"10.3390\/cells9061485"},{"issue":"2","key":"1202_CR81","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(2):85\u2013100. https:\/\/doi.org\/10.1038\/s41571-020-0426-7.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1202_CR82","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3892\/etm.2012.498","volume":"3","author":"DB Zippel","year":"2012","unstructured":"Zippel DB, Besser M, Shapira R, Ben-Nun A, Goitein D, Davidson T, et al. Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon\u2019s perspective. Exp Ther Med. 2012;3(5):898\u2013902. https:\/\/doi.org\/10.3892\/etm.2012.498.","journal-title":"Exp Ther Med"},{"issue":"1","key":"1202_CR83","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40259-018-0324-z","volume":"33","author":"BR Dholaria","year":"2019","unstructured":"Dholaria BR, Bachmeier CA, Locke F. Mechanisms and management of chimeric antigen receptor t-cell therapy-related toxicities. BioDrugs. 2019;33(1):45\u201360. https:\/\/doi.org\/10.1007\/s40259-018-0324-z. Review of CAR-T toxicity and management.","journal-title":"BioDrugs"},{"key":"1202_CR84","doi-asserted-by":"publisher","first-page":"4273943","DOI":"10.1155\/2016\/4273943","volume":"2016","author":"PH Pandya","year":"2016","unstructured":"Pandya PH, Murray ME, Pollok KE, Renbarger JL. The immune system in cancer pathogenesis: potential therapeutic approaches. J Immunol Res. 2016;2016:4273943. https:\/\/doi.org\/10.1155\/2016\/4273943.","journal-title":"J Immunol Res"},{"key":"1202_CR85","unstructured":"Goldman AS, Prabhakar BS. Immunology overview. In: th, Baron S, editors. Medical Microbiology. Galveston (TX);1996."},{"issue":"2","key":"1202_CR86","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","volume":"33","author":"EJM Grigor","year":"2019","unstructured":"Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, et al. Risks and benefits of chimeric antigen receptor t-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transfus Med Rev. 2019;33(2):98\u2013110. https:\/\/doi.org\/10.1016\/j.tmrv.2019.01.005.","journal-title":"Transfus Med Rev"},{"issue":"2","key":"1202_CR87","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021;18(2):71\u201384. https:\/\/doi.org\/10.1038\/s41571-020-0427-6.","journal-title":"Nat Rev Clin Oncol"},{"key":"1202_CR88","unstructured":"Yescarta Package Insert. Food and Drug Administration. 2021;Available at\u00a0https:\/\/www.fda.gov\/media\/108377\/download.\u00a0Accessed 1 Aug 2021."},{"issue":"1","key":"1202_CR89","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult relapsed or refractory diffuse large b-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980.","journal-title":"N Engl J Med"},{"key":"1202_CR90","unstructured":"Kymriah Package Insert. Food and Drug Administration. 2021;Available at\u00a0https:\/\/www.fda.gov\/media\/107296\/download.\u00a0Accessed 1 Aug 2021."},{"key":"1202_CR91","unstructured":"Breyanzi Package Insert. Food and Drug Administration. 2021;Available at\u00a0https:\/\/www.fda.gov\/media\/145711\/download.\u00a0Accessed 1 Aug 2021."},{"key":"1202_CR92","unstructured":"Tecartus Package Insert. Food and Drug Administration. 2021;Available at\u00a0https:\/\/www.fda.gov\/media\/140409\/download.\u00a0Accessed 1 Aug 2021."},{"key":"1202_CR93","unstructured":"Abecma Package Insert. Food and Drug Administration. 2021;Available at\u00a0https:\/\/www.fda.gov\/media\/147055\/download.\u00a0Accessed 1 Aug 2021."},{"issue":"4","key":"1202_CR94","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"1202_CR95","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","volume":"146","author":"DM Harper","year":"2017","unstructured":"Harper DM, DeMars LR. HPV vaccines - a review of the first decade. Gynecol Oncol. 2017;146(1):196\u2013204. https:\/\/doi.org\/10.1016\/j.ygyno.2017.04.004.","journal-title":"Gynecol Oncol"},{"issue":"1 Suppl","key":"1202_CR96","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.ygyno.2010.04.004","volume":"118","author":"JT Schiller","year":"2010","unstructured":"Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecol Oncol. 2010;118(1 Suppl):S12\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2010.04.004.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1202_CR97","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1017\/S0950268815002198","volume":"144","author":"PE Castle","year":"2016","unstructured":"Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect. 2016;144(3):449\u201368. https:\/\/doi.org\/10.1017\/S0950268815002198.","journal-title":"Epidemiol Infect"},{"issue":"8","key":"1202_CR98","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1405044","volume":"372","author":"EA Joura","year":"2015","unstructured":"Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1405044.","journal-title":"N Engl J Med"},{"key":"1202_CR99","unstructured":"Amgen Inc. IMLYGIC (talimogene laherparepvec) [package insert]. U.S. Food and Drug Administration website. www.fda.gov\/downloads\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/UCM469575.pdf. Revised December 2019. Accessed June 15, 2021. ."},{"issue":"1","key":"1202_CR100","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ygyno.2019.03.253","volume":"154","author":"AR Giuliano","year":"2019","unstructured":"Giuliano AR, Joura EA, Garland SM, Huh WK, Iversen OE, Kjaer SK, et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecol Oncol. 2019;154(1):110\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.253.","journal-title":"Gynecol Oncol"},{"key":"1202_CR101","doi-asserted-by":"publisher","first-page":"100203","DOI":"10.1016\/j.pvr.2020.100203","volume":"10","author":"SE Olsson","year":"2020","unstructured":"Olsson SE, Restrepo JA, Reina JC, Pitisuttithum P, Ulied A, Varman M, et al. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Papillomavirus Res. 2020;10:100203. https:\/\/doi.org\/10.1016\/j.pvr.2020.100203.","journal-title":"Papillomavirus Res"},{"issue":"29","key":"1202_CR102","first-page":"620","volume":"63","author":"S Stokley","year":"2014","unstructured":"Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, et al. Human papillomavirus vaccination coverage among adolescents, 2007\u20132013, and postlicensure vaccine safety monitoring, 2006\u20132014\u2013United States. MMWR Morb Mortal Wkly Rep. 2014;63(29):620\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"1202_CR103","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s10067-015-2969-z","volume":"34","author":"M Martinez-Lavin","year":"2015","unstructured":"Martinez-Lavin M. Hypothesis: Human papillomavirus vaccination syndrome\u2013small fiber neuropathy and dysautonomia could be its underlying pathogenesis. Clin Rheumatol. 2015;34(7):1165\u20139. https:\/\/doi.org\/10.1007\/s10067-015-2969-z.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1202_CR104","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s12026-016-8820-z","volume":"65","author":"B Palmieri","year":"2017","unstructured":"Palmieri B, Poddighe D, Vadala M, Laurino C, Carnovale C, Clementi E. Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature. Immunol Res. 2017;65(1):106\u201316. https:\/\/doi.org\/10.1007\/s12026-016-8820-z.","journal-title":"Immunol Res"},{"issue":"1\u20132","key":"1202_CR105","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12026-014-8567-3","volume":"61","author":"P Pellegrino","year":"2015","unstructured":"Pellegrino P, Perrone V, Pozzi M, Carnovale C, Perrotta C, Clementi E, et al. The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems. Immunol Res. 2015;61(1\u20132):90\u20136. https:\/\/doi.org\/10.1007\/s12026-014-8567-3.","journal-title":"Immunol Res"},{"issue":"1","key":"1202_CR106","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/ALN.0b013e31823db712","volume":"116","author":"HI Mustafa","year":"2012","unstructured":"Mustafa HI, Fessel JP, Barwise J, Shannon JR, Raj SR, Diedrich A, et al. Dysautonomia: perioperative implications. Anesthesiology. 2012;116(1):205\u201315. https:\/\/doi.org\/10.1097\/ALN.0b013e31823db712.","journal-title":"Anesthesiology"},{"issue":"3","key":"1202_CR107","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/ACO.0000000000000072","volume":"27","author":"S McGrane","year":"2014","unstructured":"McGrane S, Atria NP, Barwise JA. Perioperative implications of the patient with autonomic dysfunction. Curr Opin Anaesthesiol. 2014;27(3):365\u201370. https:\/\/doi.org\/10.1097\/ACO.0000000000000072.","journal-title":"Curr Opin Anaesthesiol"},{"issue":"1","key":"1202_CR108","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00430-014-0375-9","volume":"204","author":"G Leroux-Roels","year":"2015","unstructured":"Leroux-Roels G. Old and new adjuvants for hepatitis B vaccines. Med Microbiol Immunol. 2015;204(1):69\u201378. https:\/\/doi.org\/10.1007\/s00430-014-0375-9.","journal-title":"Med Microbiol Immunol"},{"issue":"3","key":"1202_CR109","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/jpids\/pix040","volume":"6","author":"ST O'Leary","year":"2017","unstructured":"O\u2019Leary ST, Maldonado YA, Byington CL. Update From the Advisory Committee on Immunization Practices. J Pediatric Infect Dis Soc. 2017;6(3):215\u20138. https:\/\/doi.org\/10.1093\/jpids\/pix040.","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"2","key":"1202_CR110","first-page":"105","volume":"31","author":"M Fernandez-Prada","year":"2018","unstructured":"Fernandez-Prada M, Rodriguez-Fonseca OD, Brandy-Garcia AM, Alonso-Penanes P, Huerta-Gonzalez I, Fernandez-Noval F. Use of hepatitis B AS04C adjuvanted vaccine in HIV patients. Rev Esp Quimioter. 2018;31(2):105\u20139.","journal-title":"Rev Esp Quimioter"},{"issue":"4","key":"1202_CR111","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.vaccine.2017.11.079","volume":"36","author":"P Haber","year":"2018","unstructured":"Haber P, Moro PL, Ng C, Lewis PW, Hibbs B, Schillie SF, et al. Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005\u20132015. Vaccine. 2018;36(4):559\u201364. https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.079.","journal-title":"Vaccine"},{"issue":"6","key":"1202_CR112","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/pds.1408","volume":"16","author":"F Destefano","year":"2007","unstructured":"Destefano F, Weintraub ES, Chen RT. Hepatitis B vaccine and risk of multiple sclerosis. Pharmacoepidemiol Drug Saf. 2007;16(6):705\u20137, author reply 7-8. https:\/\/doi.org\/10.1002\/pds.1408.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"15","key":"1202_CR113","doi-asserted-by":"publisher","first-page":"455","DOI":"10.15585\/mmwr.mm6715a5","volume":"67","author":"S Schillie","year":"2018","unstructured":"Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. Recommendations of the advisory committee on immunization practices for use of a hepatitis b vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep. 2018;67(15):455\u20138. https:\/\/doi.org\/10.15585\/mmwr.mm6715a5.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1202_CR114","unstructured":"U.S. Food and Drug Administration. In: BLA Clinical Review Memorandum. 2017. https:\/\/www.fda.gov\/media\/109802\/download. Accessed June 17, 2019."},{"key":"1202_CR115","doi-asserted-by":"publisher","unstructured":"Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon. Drugs R D. 2006;7(3):197\u2013201. https:\/\/doi.org\/10.2165\/00126839-200607030-00006.","DOI":"10.2165\/00126839-200607030-00006"},{"key":"1202_CR116","unstructured":"https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/provenge-sipuleucel-T. 2019; Updated May 28, 2019. Accessed June 17, 2019."},{"issue":"8","key":"1202_CR117","doi-asserted-by":"publisher","first-page":"e199249","DOI":"10.1001\/jamanetworkopen.2019.9249","volume":"2","author":"GM Dores","year":"2019","unstructured":"Dores GM, Bryant-Genevier M, Perez-Vilar S. Adverse events associated with the use of sipuleucel-t reported to the us food and drug administration\u2019s adverse event reporting system, 2010\u20132017. JAMA Netw Open. 2019;2(8):e199249. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.9249.","journal-title":"JAMA Netw Open"},{"issue":"25","key":"1202_CR118","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780\u20138. https:\/\/doi.org\/10.1200\/JCO.2014.58.3377.","journal-title":"J Clin Oncol"},{"key":"1202_CR119","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ebiom.2019.07.066","volume":"47","author":"RHI Andtbacka","year":"2019","unstructured":"Andtbacka RHI, Amatruda T, Nemunaitis J, Zager JS, Walker J, Chesney JA, et al. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. EBioMedicine. 2019;47:89\u201397. https:\/\/doi.org\/10.1016\/j.ebiom.2019.07.066.","journal-title":"EBioMedicine"},{"issue":"6","key":"1202_CR120","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2217\/imt.15.35","volume":"7","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Puzanov I, Kelley MC. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy. 2015;7(6):611\u20139. https:\/\/doi.org\/10.2217\/imt.15.35.","journal-title":"Immunotherapy"},{"issue":"13","key":"1202_CR121","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1245\/s10434-018-6803-0","volume":"25","author":"MC Perez","year":"2018","unstructured":"Perez MC, Miura JT, Naqvi SMH, Kim Y, Holstein A, Lee D, et al. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience. Ann Surg Oncol. 2018;25(13):3960\u20135. https:\/\/doi.org\/10.1245\/s10434-018-6803-0.","journal-title":"Ann Surg Oncol"},{"key":"1202_CR122","doi-asserted-by":"publisher","unstructured":"Eissa IR, Bustos-Villalobos I, Ichinose T, Matsumura S, Naoe Y, Miyajima N et al. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers. Cancers (Basel). 2018;10(10). https:\/\/doi.org\/10.3390\/cancers10100356.","DOI":"10.3390\/cancers10100356"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01202-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01202-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01202-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T07:40:20Z","timestamp":1744184420000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01202-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":122,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1202"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01202-6","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]},"assertion":[{"value":"20 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}